Ryan A.C.
SVP of Corporate Affairs
Replay available
Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call
Revolution Medicines, Inc. (NASDAQ: RVMD) Q2 2025 earnings conference call, held 2025-08-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Mark Goldsmith
Chairman and Chief Executive Officer
Jack Anders
Chief Financial Officer
Dr. Steve Kelsey
President of R&D
Anthony Mancini
Chief Global Commercialization Officer
Dr. Wade-Lynn
Chief Medical Officer
Michael Schmidt
Analyst, Guggenheim Securities
Mark Fram
Analyst, TD Securities
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Revolution Medicines, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.216 Good day and thank you for standing by. Welcome to the Revolution Medicine's Q2 2025 00:00:05.216 -- 00:00:10.241 Earnings Conference Call. At this time, all participants are in a listen-only mode. 00:00:10.241 -- 00:00:14.204 After the speaker's presentation, there will be a question and answer session. 00:00:14.204 -- 00:00:18.829 To ask a question during the session, you will need to press star 11 on your telephone. 00:00:18.829 -- 00:00:22.292 You will then hear an automated message advising your hand is raised. 00:00:22.292 -- 00:00:25.235 To withdraw your question, please press star 11 again. 00:00:25.235 -- 00:00:29.512 Please be advised that today's conference is being recorded. 00:00:29.512 -- 00:00:33.900 I would now like to hand the conference over to your first speaker today, Ryan A.C., 00:00:33.900 -- 00:00:36.164 SVP of Corporate Affairs. Please go ahead. 00:00:36.164 -- 00:00:38.164 Thank 00:00:39.070 -- 00:00:42.917 you, and welcome everyone to the second quarter 2025 earnings call. 00:00:42.917 -- 00:00:47.004 Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and 00:00:47.004 -- 00:00:51.685 Chief Executive Officer, and Jack Anders, our Chief Financial Officer. 00:00:51.685 -- 00:00:57.172 Dr. Steve Kelsey, our President of R&D, Anthony Mancini, our Chief Global Commercialization 00:00:57.172 -- 00:01:01.697 Officer, and Peg Horn, our Chief Operating Officer, will join us for the Q&A portion 00:01:01.697 -- 00:01:06.223 of today's call. I'd like to inform you that certain statements we make during this call 00:01:06.223 -- 00:01:10.468 will be forward-looking because such statements deal with future events and are subject 00:01:10.468 -- 00:01:15.094 to many risks and uncertainties. ...